Based on the above evidence, it can be hypothesized that SARS-CoV-2 may target ACE2 and repress its expression or activity, causing disturbances in cognitive function and exacerbating cognitive impairment in people with AD, compared with healthy controls and patients with vascular dementia. The gene discussed is ACE2; the disease is Alzheimer disease.